Enhabit Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Enhabit Inc (EHAB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Enhabit Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,065M vs 34,701M combined for tracked competitors (3.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-0.5% annualized vs trailing 12 months), vs holding steady (-0.7%) for its tracked peer group.
- Growth: Enhabit Inc generated 1.9% revenue growth year over year in Q1 2026, vs 6.8% for its tracked competitors combined.
- Profitability: Its 7.5% net margin compares with 6.3% for the peer group.
- Peer revenue share: Enhabit Inc accounted for 3.0% of combined revenue among its tracked peer group, down from 3.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.10M compares with $0.13M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
EHAB Sales vs. its Competitors, Q1 2026
Enhabit Inc reported revenue growth of 1.89 % year on year in Q1 2026, below its competitors' combined revenue growth of 6.76 %.
With a net margin of 7.52 %, Enhabit Inc achieved higher profitability than its competitors (6.28 %).
Enhabit Inc generated 2.98 % of the combined sales of its peer group, down from 3.12 % a year earlier.
Enhabit Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Enhabit Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Enhabit Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Enhabit Inc's competitor groups requires a Commercial License.
For context: the Healthcare Facilities industry grew revenue 14.7% year over year, combined, vs 1.9% for Enhabit Inc. Enhabit Inc's share of combined industry revenue moved from 0.25% to 0.22%, a loss of 0.03 percentage points.
Enhabit Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Enhabit Inc | No | Yes | No | No |
| Competitors combined (14) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 87.50 % (7 of 8) | 50.00 % (4 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EHAB Stock Performance relative to its Competitors
EHAB Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | National Healthcare Corp | 282.9% | Outperformed |
| 2 | Quipt Home Medical Corp | 282.9% | Outperformed |
| 3 | Aveanna Healthcare Holdings Inc | 282.9% | Outperformed |
| 4 | Sonida Senior Living Inc | 282.9% | Outperformed |
| 5 | Viemed Healthcare Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Enhabit Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Enhabit Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Enhabit Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Enhabit Inc | 729.76 | 1,064.90 |
| Encompass Health Corporation | 12,356.00 | 6,206.10 |
| Ensign Group Inc | 10,441.05 | 5,486.71 |
| Chemed Corporation | 6,758.55 | 2,595.00 |
| Option Care Health Inc | 3,608.75 | 5,666.58 |
| National Healthcare Corp | 3,556.15 | 1,559.02 |
| SUBTOTAL | 54,066.92 | 38,433.25 |
Sign in to see all competitors of Enhabit Inc .
Sources: Enhabit Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Enhabit Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Enhabit Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Enhabit Inc | Home Health 76.21 % |
| Encompass Health Corporation | Inpatient Rehabilitation 100.00 % |
| Ensign Group Inc | Skilled Services 95.80 % |
| Chemed Corporation | Segment Vitas 65.85 % |
| Option Care Health Inc | Reportable 100.00 % |
| National Healthcare Corp | Inpatient Services Segment 86.62 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Enhabit Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Enhabit Inc | 730 | 98,602 | -102 |
| Encompass Health Corporation | 12,356 | 147,764 | 19,840 |
| Ensign Group Inc | 10,441 | 119,276 | 8,240 |
| Chemed Corporation | 6,759 | 164,126 | 17,393 |
| Option Care Health Inc | 3,609 | 685,528 | 24,944 |
| National Healthcare Corp | 3,556 | 102,043 | 9,350 |
| PEERS TOTAL | 53,337 | 127,696 | 7,675 |
Enhabit Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 48 companies in Enhabit Inc's industry classification, broader than the peer set above. Market cap in millions of $.Enhabit Inc ranks #0 of 48 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,734, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Hca Healthcare Inc | 97,830 | 38.62 % |
| 2 | Tenet Healthcare Corp | 21,629 | 8.54 % |
| 3 | Fresenius Medical Care Ag | 12,970 | 5.12 % |
| 4 | Encompass Health Corporation | 12,356 | 4.88 % |
| 5 | Brightspring Health Services Inc | 1,234 | 5.2% |
| 6 | Davita Inc | 1,234 | 5.2% |
| 7 | Universal Health Services Inc | 1,234 | 5.2% |
| 8 | Ensign Group Inc | 1,234 | 5.2% |
| 9 | Pacs Group Inc | 1,234 | 5.2% |
| 10 | Chemed Corporation | 1,234 | 5.2% |
| 0 | Enhabit Inc | 730 | 0.00 % |
Market cap and industry share for the rest of Enhabit Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-14.
Enhabit Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Healthcare Facilities industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Healthcare Facilities industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 48.90 % | 52.28 % (avg) | -3.4 pp |
| Operating Margin | 2.77 % | industry median | -4.7 pp |
| EBITDA Margin | 2.50 % | 3.22 % (avg) | -0.7 pp |
| Capital Intensity (Capex / Revenue) | 0.67 % | 4.01 % (avg) | -3.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Enhabit Inc's Valuation vs Competitive Position
Valuation multiples vs the Healthcare Facilities industry average (77 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Healthcare Facilities industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 23.5x | - |
| EV / EBITDA | 41.5x | 15.7x | +25.8x |
| P/B | 1.2x | 3.3x | -2.1x |
| Return on Equity | -0.19 % | industry aggregate | -39.60 % |
| Return on Invested Capital | 1.71 % | 4.91 % (avg) | -3.20 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Enhabit Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | - | -1.10 % | 2.44 % |
| Operating Margin | - | -4.55 % | -11.12 % | 1.52 % |
| Return on Invested Capital | - | -2.31 % | -6.17 % | 0.93 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Enhabit Inc's Strategic Group Map
Every company in Enhabit Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Enhabit Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Enhabit Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,734 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.67 % vs industry average 4.01 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Enhabit Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Enhabit Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Enhabit Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Enhabit Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Enhabit Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 39.6 points below the industry aggregate.
Opportunities
No rule matched.
Threats
- Industry dominated by Hca Healthcare Inc , holding 38.62 % of industry market cap.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Enhabit Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Enhabit Inc | 0.35 | 1.58 | 0.79 |
| Encompass Health Corporation | 0.10 | 1.15 | 0.98 |
| Ensign Group Inc | 0.51 | 1.41 | 0.03 |
| Chemed Corporation | 0.21 | 1.04 | 0.06 |
| Option Care Health Inc | 0.29 | 1.56 | 0.85 |
| National Healthcare Corp | 0.41 | 1.82 | 0.03 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Enhabit Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Enhabit Inc | Q1 2026 | +1.9 % | +8.2 % |
| Encompass Health Corporation | Q2 2026 | +9.6 % | +12.2 % |
| Ensign Group Inc | Q2 2026 | +17.3 % | +18.2 % |
| Chemed Corporation | Q2 2026 | +8.8 % | +29.0 % |
| Option Care Health Inc | Q1 2026 | +1.3 % | -3.0 % |
| National Healthcare Corp | Q2 2026 | +8.8 % | +68.1 % |
| PEERS TOTAL | +7.6 % | +36.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Enhabit Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Enhabit Inc | Q1 2026 | +3.1 % | +733.3 % |
| Encompass Health Corporation | Q2 2026 | - | +40.4 % |
| Ensign Group Inc | Q2 2026 | +16.7 % | - |
| Chemed Corporation | Q2 2026 | +4.1 % | -1.8 % |
| Option Care Health Inc | Q1 2026 | +1.7 % | -3.5 % |
| National Healthcare Corp | Q2 2026 | - | +22.8 % |
Enhabit Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Enhabit Inc | - | - | - |
| Encompass Health Corporation | 11.60% | 11.56% | 25.52% |
| Ensign Group Inc | 6.88% | 5.75% | 16.53% |
| Chemed Corporation | 17.52% | 20.13% | 29.45% |
| Option Care Health Inc | 6.02% | 7.82% | 15.28% |
| National Healthcare Corp | 9.28% | 10.91% | 13.11% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Enhabit Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Enhabit Inc | - | 0.69 |
| Encompass Health Corporation | 20.13 | 1.99 |
| Ensign Group Inc | 27.47 | 1.90 |
| Chemed Corporation | 363.16 | 2.60 |
| Option Care Health Inc | 17.82 | 0.64 |
| National Healthcare Corp | 25.19 | 2.28 |
| PEERS AVERAGE | 24.08 | 1.41 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.